P1/2, N=195, Active, not recruiting, Grupo Espanol de Investigacion en Sarcomas | Recruiting --> Active, not recruiting

The combination treatment (CC) largely reflected Cu-driven morphological and functional changes, with Co coexisting without counteracting Cu's effects. Taken together, these findings reveal compound-specific mechanisms of action for Cu and Co in OSCC therapy.

YTHDF3 is highly expressed in AAA tissues and Ang II-induced VSMCs. YTHDF3 hinders the proliferation of Ang II-induced VSMCs while promoting apoptosis and inflammation. YTHDF3 deficiency exerts protective effect by interfering with SIRT2/FOXO1 axis.

P2/3, N=300, Wroclaw Medical University

In fed-batch fermentation, SCC7 achieved 6972.8 mg/L COR in a 6 L bioreactor, representing the highest COR titer reported in S. cerevisiae to date. In conclusion, this study establishes an efficient yeast platform for COR production and provides a useful reference for biosynthesis of other bioactive nucleosides.

P1, N=104, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting

Given its oncogenic potential, this study aimed to investigate the potential of SOX2 as a biomarker and evaluate the inhibitory effects of cordycepin (CD), a natural compound, on SOX2-driven oncogenic phenotypes in lung cancer...Moreover, overexpression of SOX2 promoted lung cancer cell growth, migration, and invasion, while CD, a natural product originally from the traditional Chinese medicine Cordyceps sinensis (BerK.), suppressed SOX2-mediated progression, including the growth, migration, and invasion of lung cancer. Taken together, these results implied that SOX2 is a potential biomarker for diagnostics, prognostics, and therapeutics for lung cancer, including LUAD and LUSC.

Our work uncovers a previously unrecognized PRKN-METTL3-CLDN2 signaling network that orchestrates colorectal tumorigenesis, providing a compelling rationale for developing METTL3-targeted therapies against CRC.

Our findings establish the ALKBH5/IGF2BP1-TRIM37-RBMX signaling axis as a pivotal driver of PDAC progression, highlighting the intersection of m6A modification, ubiquitin signaling, and metabolic reprogramming. These findings may provide potential therapeutic avenues for this intractable malignancy.

We have established the circ-ZBTB38/RALGAPB axis as a novel regulatory circuit in melanoma. Circ-ZBTB38 mediates RALGAPB post-translational degradation to hyperactivate Ral signaling. This work uncovers a new mechanism of circRNA-mediated regulation of enzyme activity (RalGAPs) in signaling crosstalk and highlights circ-ZBTB38 as a prognostic biomarker and therapeutic target for melanoma.

P4, N=150, Not yet recruiting, University of Miami

Here, we demonstrate that expression of DYRK1B - but not its closely related paralog DYRK1A - is upregulated by cytostatic drugs (Actinomycin D, Doxorubicin) in multiple cancer cell lines. In conclusion, our study identifies DYRK1B as an indirect p53 target that suppresses p53-mediated activation of RFX7. These findings suggest that pharmacological inhibition of DYRK1B may represent a therapeutic strategy to enhance RFX7 tumor suppressor function.